- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Rationale:
- Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late July 2026 when we will write to you about how you can get involved.
- Process:
- STA Standard
- ID number:
- 6548
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 October 2025 | To appraise the clinical and cost effectiveness of Trastuzumab deruxtecan + Pertuzumab within its marketing authorisation for treating breast cancer |
| 19 August 2025 | Awaiting development |
| 04 March 2025 | Topic selection |
For further information on how we select topics for development, please see our page about topic prioritisation